

Andrea Chiricozzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5620725/publications.pdf>

Version: 2024-02-01

124
papers

4,914
citations

147801

31
h-index

106344

65
g-index

128
all docs

128
docs citations

128
times ranked

6170
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Responses to IL-17 and TNF- α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2011, 131, 677-687.	0.7	526
2	The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 379-390.	6.5	447
3	Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 954-964.e4.	2.9	375
4	Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1235-1244.e58.	2.9	231
5	Scanning the Immunopathogenesis of Psoriasis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 179.	4.1	212
6	Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 583-593.e4.	2.9	182
7	IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. <i>PLoS ONE</i> , 2014, 9, e90284.	2.5	149
8	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 774-790.	2.4	140
9	IL-17 targeted therapies for psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 993-1005.	4.1	136
10	TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. <i>Journal of Experimental Medicine</i> , 2017, 214, 1529-1546.	8.5	109
11	Unconventional Use of Intense Pulsed Light. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	99
12	Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. <i>British Journal of Dermatology</i> , 2016, 174, 136-145.	1.5	83
13	Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review. <i>Sensors</i> , 2017, 17, 2952.	3.8	81
14	Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 373-381.e4.	2.9	74
15	IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	2.2	72
16	Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1299-1308.	3.0	67
17	PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, e42-e44.	1.2	57
18	Targeting IL-4 for the Treatment of Atopic Dermatitis. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 151-156.	5.8	56

#	ARTICLE	IF	CITATIONS
19	Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 9-20.	0.4	52
20	Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 39-45.	1.2	51
21	Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 513-525.	3.4	50
22	A revolutionary therapeutic approach for psoriasis: bispecific biological agents. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 751-754.	4.1	46
23	A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 237-249.	3.0	41
24	New topical treatments for psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 461-470.	1.8	40
25	Mass quarantine measures in the time of COVID-19 pandemic: psychosocial implications for chronic skin conditions and a call for qualitative studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e293-e294.	2.4	40
26	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 271-277.	3.1	40
27	Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir,) <i>TJ ETQq1 1 0.784314 rgB.L.1 Overload 10 Tf 5</i>		
28	No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1653-1659.	2.4	39
29	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	1.2	39
30	Tofacitinib for the treatment of moderate-to-severe psoriasis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 443-455.	3.0	38
31	An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. <i>Journal of Dermatological Treatment</i> , 2010, 21, 363-366.	2.2	35
32	Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 304-311.	2.4	34
33	Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1965-1969.	2.9	34
34	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021, 11, 235-252.	3.0	34
35	Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 441-447.	6.7	33
36	Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 699-707.	1.3	32

#	ARTICLE	IF	CITATIONS
37	Atopic dermatitis keratinocytes exhibit normal TH17 cytokine responses. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 744-746.e2.	2.9	31
38	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. <i>Dermatology and Therapy</i> , 2017, 7, 265-279.	3.0	31
39	Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e770-e772.	2.4	31
40	A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e169-e170.	2.4	31
41	Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. <i>Clinical Drug Investigation</i> , 2021, 41, 917-925.	2.2	31
42	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.5	30
43	Elderly psoriatic patients under biological therapies: an Italian experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 143-146.	2.4	29
44	Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies. <i>Vaccines</i> , 2020, 8, 769.	4.4	29
45	Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1813-1824.	5.7	28
46	AIISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa. <i>Wounds</i> , 2015, 27, 258-64.	0.5	28
47	Apremilast for the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2083-2094.	1.8	27
48	The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. <i>Vaccines</i> , 2020, 8, 728.	4.4	27
49	Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. <i>PLoS ONE</i> , 2017, 12, e0183415.	2.5	27
50	Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1473-1480.	4.3	25
51	Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis. <i>Dermatology</i> , 2018, 234, 66-70.	2.1	24
52	The pharmacological management of patients with comorbid psoriasis and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 863-872.	1.8	23
53	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 476-483.	2.2	23
54	New insights into the pathogenesis of cutaneous autoimmune disorders. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2012, 26, 165-70.	0.7	23

#	ARTICLE	IF	CITATIONS
55	Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1292-1299.	2.4	23
56	Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis. <i>Histology and Histopathology</i> , 2017, 32, 893-898.	0.7	21
57	Efficacy and safety of infliximab in psoriatic patients over the age of 65. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1459-1462.	2.4	20
58	Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 757-766.	5.0	20
59	The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1079-1083.	2.2	20
60	Optimizing acitretin use in patients with plaque psoriasis. <i>Dermatologic Therapy</i> , 2017, 30, e12453.	1.7	19
61	Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. <i>Dermatologic Therapy</i> , 2017, 30, e12549.	1.7	19
62	Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. <i>PLoS ONE</i> , 2020, 15, e0237267.	2.5	19
63	A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 135-148.	3.1	18
64	Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. <i>Dermatology</i> , 2021, 237, 535-541.	2.1	18
65	Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 1-7.	0.8	18
66	Etanercept biosimilar <sc>SB</sc> 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2019, 180, 409-410.	1.5	17
67	HIDRADisk: an innovative visual tool to assess the burden of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e24-e26.	2.4	16
68	Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1121-1128.	3.3	14
69	Alexithymia affects patients with hidradenitis suppurativa. <i>European Journal of Dermatology</i> , 2018, 28, 482-487.	0.6	13
70	Apheresis in the treatment of recalcitrant atopic dermatitis: case series and review of the literature. <i>European Journal of Dermatology</i> , 2014, 24, 545-550.	0.6	12
71	A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	12
72	Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice. <i>Pharmacological Research</i> , 2020, 158, 104878.	7.1	12

#	ARTICLE	IF	CITATIONS
73	Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00172.	1.3	12
74	Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. <i>Allergologia Et Immunopathologia</i> , 2019, 47, 194-206.	1.7	11
75	The Hidradenitis Suppurativa (HS) "Multidisciplinary Unit": a rationale and practical proposal for an organised clinical approach. <i>European Journal of Dermatology</i> , 2018, 28, 274-275.	0.6	10
76	Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1089-1098.	4.1	10
77	Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 347-355.	3.3	10
78	Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1325-1334.	3.1	9
79	<p>Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential</p>. <i>Psoriasis: Targets and Therapy</i> , 2019, Volume 9, 29-35.	2.2	9
80	Potential role of serum amyloid A in hidradenitis suppurativa. <i>JAAD Case Reports</i> , 2019, 5, 406-409.	0.8	9
81	Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience. <i>Dermatology</i> , 2019, 235, 213-218.	2.1	9
82	Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. <i>Dermatology</i> , 2020, 236, 329-335.	2.1	9
83	Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 367-376.	3.1	9
84	Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. <i>European Journal of Dermatology</i> , 2015, 25, 64-69.	0.6	8
85	Acne fulminans associated with lymecycline intake: a case report. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 403-405.	1.8	8
86	Risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1-8.	3.1	8
87	Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 335-340.	0.8	8
88	New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 411-420.	0.8	8
89	Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. <i>Dermatology</i> , 2022, 238, 717-724.	2.1	8
90	Biological agents targeting interleukin-13 for atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 651-659.	3.1	8

#	ARTICLE	IF	CITATIONS
91	Assessment of alopecia areata universalis successfully treated with upadacitinib. International Journal of Dermatology, 2023, 62, .	1.0	8
92	Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study. Journal of Wound Care, 2017, 26, S9-S17.	1.2	7
93	Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1815-1821.	2.4	7
94	Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Italian Journal of Dermatology and Venereology, 2022, 157, .	0.2	7
95	Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e128-e129.	2.4	6
96	Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa. Skin Appendage Disorders, 2019, 5, 38-41.	1.0	6
97	COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus. International Journal of Dermatology, 2020, 59, 1423-1424.	1.0	6
98	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	2.4	6
99	Consensus on the place in therapy of TNF-inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e470-e472.	2.4	6
100	Effective topical agents and emerging perspectives in the treatment of psoriasis. Expert Review of Dermatology, 2012, 7, 283-293.	0.3	5
101	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576.	1.3	5
102	Isotretinoin-triggered acne fulminans: a rare, disabling occurrence. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 361-362.	0.8	5
103	Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opinion on Biological Therapy, 2022, 22, 1585-1592.	3.1	5
104	Lasers and Energy Devices for the Skin: Conventional and Unconventional Use. BioMed Research International, 2016, 2016, 1-2.	1.9	4
105	Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF agents. Italian Journal of Dermatology and Venereology, 2018, 153, 316-325.	0.2	4
106	The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 15-20.	2.4	4
107	Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. Italian Journal of Dermatology and Venereology, 2021, , .	0.2	4
108	HS-TIME: A Modified TIME Concept in Hidradenitis Suppurativa Topical Management. Wounds, 2019, 31, 222-227.	0.5	4

#	ARTICLE	IF	CITATIONS
109	Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice. <i>Journal of Dermatological Treatment</i> , 2018, 29, 1-2.	2.2	3
110	Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern. <i>Dermatology</i> , 2021, 237, 759-768.	2.1	3
111	Successful treatment with secukinumab in an <scp>HIV</scp> â€positive psoriatic patient after failure of apremilast. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	3
112	Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis. <i>JAAD Case Reports</i> , 2019, 5, 484-487.	0.8	2
113	Bimekizumab. <i>Current Dermatology Reports</i> , 2020, 9, 36-42.	2.1	2
114	Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 685-686.	0.8	2
115	Patients Withdrawing Dupilumab Monotherapy for COVID-19â€Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy. <i>Dermatitis</i> , 2022, 33, e25-e29.	1.6	2
116	Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.2	2
117	Synergism of Therapies After Postoperative Autograft Failure in a Patient With Melanoma of the Foot Misdiagnosed as a Pressure Ulcer. <i>Wounds</i> , 2018, 30, E41-E43.	0.5	2
118	Gene Expression Profiling Associated with the Progression of Classic Kaposi's Sarcoma. <i>European Journal of Inflammation</i> , 2012, 10, 371-382.	0.5	1
119	Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 699-707.	4.1	1
120	Reply to: â€Comment on â€Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective studyâ€™â€ Journal of the American Academy of Dermatology, 2019, 81, e83.	1.2	1
121	Granuloma annulare: a case treated with infliximab successfully. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 193-195.	0.2	1
122	The management of moderate-to-severe chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 447-457.	0.2	1
123	A giant annular rash in a woodman: the many faces of erythema chronicum migrans. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 730-732.	0.8	0
124	Gynecomastia following isotretinoin treatment: a rare endocrine side effect. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 505-506.	0.8	0